Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $5.9 million.

  • NewAmsterdam Pharma's Accumulated Expenses rose 4016.24% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 4016.24%. This contributed to the annual value of $8.7 million for FY2024, which is 15771.28% up from last year.
  • NewAmsterdam Pharma's Accumulated Expenses amounted to $5.9 million in Q3 2025, which was up 4016.24% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Accumulated Expenses ranged from a high of $8.7 million in Q4 2024 and a low of $1.1 million during Q1 2024
  • Its 4-year average for Accumulated Expenses is $3.7 million, with a median of $3.4 million in 2023.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 15771.28% in 2024, then soared by 4016.24% in 2025.
  • Quarter analysis of 4 years shows NewAmsterdam Pharma's Accumulated Expenses stood at $2.0 million in 2022, then skyrocketed by 69.37% to $3.4 million in 2023, then skyrocketed by 157.71% to $8.7 million in 2024, then crashed by 32.69% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $3.8 million for Q2 2025, and $2.0 million during Q1 2025.